Seoul: Celltrion Inc., a prominent South Korean biopharmaceutical company, announced Tuesday that its biosimilar, Truxima, used for treating blood cancers, secured the largest share of prescriptions in the United States in February.
According to Yonhap News Agency, Truxima captured 35.8 percent of U.S. prescriptions within its category during the month. This achievement marks the first instance of a biosimilar developed by a South Korean company leading the U.S. market. Celltrion attributes the growing demand for its biosimilar products in the U.S., the largest pharmaceutical market globally, as a positive indicator for meeting its earnings targets for the year.
Celltrion aims to achieve an operating profit of 1.7 trillion won (approximately US$1.1 billion) on sales of 5.3 trillion won by 2026, up from 1.16 trillion won and 4.16 trillion won, respectively, in the previous year. The company's strategy includes increasing the share of new biosimilars in total sales to 70 percent this year, compared to 54 percent projected for 2025.
The company has been actively expanding its global biosimilar portfolio, raising the number of approved products to 11 from six. Celltrion plans to launch 18 biosimilars by 2030 and aims for a total of 41 by 2038. Additionally, its only original drug, Zymfentra, is currently marketed in the U.S. for autoimmune diseases and sold as Remsima SC in Europe and other regions.